Physician profile
Cierra Chambers
NPI 1811490279
$965.70
in general payments reported to CMS, 2019-2025
18 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $111 · 2023: $32.01 · 2024: $300 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.36 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $123.14 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $115.55 | 2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $108.31 | 2021 | |
| Seagen INC. | $80.64 | 2022 | |
| Genmab U.S., INC. | $79.12 | 2023-2024 | Epkinly |
| Merck Sharp & Dohme LLC | $68.87 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Celgene Corporation | $51.87 | 2024-2025 | Reblozyl |
| Daiichi Sankyo INC. | $50.13 | 2022-2025 | Datroway |
| Incyte Corporation | $44.65 | 2025 | Zynyz, Monjuvi |
| Janssen Scientific Affairs, LLC | $41.15 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $31.33 | 2025 | |
| Janssen Biotech, INC. | $30.64 | 2024 | Tecvayli, Talvey |
| Jazz Pharmaceuticals INC. | $30.58 | 2024 | |
| Caris Mpi, INC. | $28.79 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $24.60 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.87 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.76 | 2024 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $15.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cierra Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.